CClinicalTrials.gg
CompletedNCT03970187ASSIST-2019Updated Oct 30, 2019

Investigation of the Efficacy of a VR Exposure-based Eye Contact Training‬ to Reduce Fear of Public Speaking

An interventional study of Exposure-based eye contact training in Virtual Reality (VR) in Fear of Public Speaking (Subclinical), sponsored by Prof. Dominique de Quervain, MD. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-30.

Sponsored by Prof. Dominique de Quervain, MD · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Investigation of the efficacy of an eye contact training App in virtual reality, based on principles of exposure therapy for the treatment for subjects with fear of public speaking.

Read the detailed description

The study will be conducted as a randomized controlled single-blind study in a parallel groups design.

Participants will be divided into groups afraid of public speaking with and without fulfilling the criteria of social anxiety (according to DSM-V), which can represent a clinically relevant and more generalized form of public speaking anxiety. The treatment for the participants solely differs in terms of whether they receive (1) the VR exposure or (2) a fear-unrelated VR task (study phase 1) or no treatment at all (study phase 2), resulting in the following 2 groups:

  • Group 1 (treatment group) consists of individuals with fear of public speaking that will (in study phase 1) receive a three-session VR exposure and undergo (in study phase 2) a 2-week treatment period with the same VR scenarios, each repeated three times.
  • Group 2 (control group) consists of individuals with fear of public speaking that will not receive any active treatment but complete a distractor task in VR in study phase 1 and no treatment in study phase 2.

In study phase 1, the treatment group receives three VR exposure sessions each lasting for 20 minutes, whereas the control group completes three virtual distractor tasks (e.g. virtual tours) of identical duration. In study phase 2, the treatment group completes a home training spanning two weeks (9 x 20-minutes sessions), whereas the control group does not receive any treatment (untreated comparison group).

In study phase 1, before and after the virtual exposure session, participants undergo an in vivo PST to assess the acute effects of the VR exposure-based eye contact training App.

In study phase 2, the participants undergo a third in vivo PST to assess the training effects of the VR exposure-based eye contact training after two weeks of home training.

This design allows a direct isolation and comparison of acute effects (study phase 1) and of training effects (study phase 2) and therefore enables an overall estimation of the effectiveness of the VR exposure-based eye contact training.

Approximately 96 participants between 18 and 40 years with fear of public speaking will take part in the study. Approximately 1 to 5 weeks after having finished the first study phase, all participants that have not dropped out will take part in the second study phase.

02

Conditions studied

  • Fear of Public Speaking (Subclinical)
03

In context

Lead sponsor

Prof. Dominique de Quervain, MD is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Fear of public speaking, assessed by two separate aspects:
  • High fear in social situations including the potential of being evaluated by others
  • Social situations can only be withstood under high fear or are avoided
  • Aged between 18-40
  • Fluent in German

Exclusion criteria

Exclusion Criteria:

  • BDI-II sumscore >= 20
  • Suicidal ideation (BDI-II item 9 > 0)
  • Serious medical or psychological condition, other than social anxiety (including Depression, Epilepsy and Migraine)
  • Concurrent psychotherapy
  • Previous exposure-based therapy for social anxiety (including public speaking anxiety) or other anxiety disorders
  • Parallel participation in another psychological or medical study
  • Chronic medication intake (except oral contraceptives)
  • Chronic drug intake (i.e. LSD, mushrooms, Ecstasy, MDMA, amphetamines etc.)
  • Medication intake before visits (less than 24 h)
  • Alcohol intake before visits (less than 12 h)
  • Cannabis or other psychoactive substances (including benzodiazepines) intake before visits (less than 5 days)
  • Restricted 3D sight
  • For women: Current pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Exposure

    Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks

    Other: Exposure-based eye contact training in Virtual Reality (VR)

  • No intervention
    Control

    Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention. Phase 2 (home training): waitlist

Interventions

  • OtherExposure-based eye contact training in Virtual Reality (VR)

    The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App. There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking.

06

What researchers measure

Primary outcomes

  1. Subjective Units of Distress Scale (SUDS, fear)

    Fear of public speaking is quantified by means of SUDS-ratings during a Public Speaking Test (PST) in vivo.

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

Secondary outcomes

  1. Global external assessment of performance in an in vivo public speech test

    The global external assessment of performance is done by averaging VAS-ratings (range from 0 = very bad performance to 100 = very good performance) of the PST from three independent members of a committee (experimenters) and a forth experimenter that will rate the performances using a video and audio recording from the speeches.

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  2. Total time of eye contact during an in vivo public speech test

    Total time of eye contact is measured by a mobile eye tracking device from Pupil Labs and operationalized by the number of frames the gaze is in predefined regions of interest comprising the eyes of the committee members.

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  3. Fear of eye contact (SUDS, eye contact)

    Fear of public speaking is quantified by means of SUDS-ratings during a Public Speaking Test (PST) in vivo.

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  4. Global self-assessment of performance in an in vivo public speech test

    The global self-assessment of performance is done by a VAS-ratings (range from 0 = very bad performance to 100 = very good performance) of the PST

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  5. Global subjectively perceived improvement of fear, eye contact and performance after single VR-exposure/waitlist

    Global subjectively perceived improvement of fear, eye contact and performance by the VR eye contact training App will be done by VAS-ratings

    Time frame: Assessed at visit 1 after completing the second PST

  6. Global subjectively perceived improvement of fear, eye contact and performance after VR-training/waitlist

    Global subjectively perceived improvement of fear, eye contact and performance by the VR eye contact training App will be done by VAS-ratings

    Time frame: Assessed at visit 2 after completing the PST

  7. Questionnaire for social anxiety (Soziale-Phobie-Inventar; SPIN)

    The SPIN is a 17-item questionnaire developed by the Psychiatry and Behavioral Sciences Department at Duke University. It is effective in screening for, and measuring the severity of fear related to the negative evaluation by others. The 17 items cover different aspects of the anxiety such as fear, avoidance, and physiological symptoms on 5-point Likert scales. The statements of the SPIN items indicate the particular signs of public speaking anxiety (e.g. "I am bothered by blushing in front of people"). The SPIN demonstrates solid psychometric properties and is valid as a measurement for the severity and clinical relevance of fear related symptoms (Connor et al., 2000).

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  8. Questionnaire for fear of negative evaluation (The Furcht vor negativer Evaluation - Kurzskala; FNE-K)

    The FNE-K is a frequently used, valid, and reliable self-report questionnaire consisting of 12 items measuring fear and distress related to negative evaluation by others (e.g. "I am afraid that people will find fault with me") on 4-point Likert scales. The FNE-K has demonstrated good reliability and validity (Reichenberger et al., 2016).

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  9. Eye-tracking measures

    Gaze behaviour (fixation frequency and location, scan path characteristics) and pupil size

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  10. Physiological measures

    Salivary cortisol levels

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

Other outcomes

  1. Feature-specific external and self-assessment of performance in an in vivo public speech test (VAS-ratings)

    Feature-specific assessment of the participants performance in the in vivo PST is measured by VAS-ratings (from 0 = very bad to 100 = very good) from three independent members of a committee. A forth experimenter will rate the performances using a video and audio recording from the speeches. 8 specific VAS-ratings covering nonverbal aspects of performances (e.g. facial expression, gestures etc.) are divided into two subscales with 4 VAS-ratings each (1 = speech, 2 = appearance).

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  2. Vocal indices of stress

    Vocal indices of stress comprise f.e. level and variability of the fundamental frequency or the active speech duration. They will be measured by analysing the audio recordings during the PST.

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

  3. Simulation sickness in VR

    Safety outcome, assessed by the Simulator Sickness Questionnaire (SSQ)

    Time frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

07

Study locations

1 site
  • University of Basel, Division of Cognitive Neuroscience
    Basel, BS 4055, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03970187
Lead sponsor
Prof. Dominique de Quervain, MD
Responsible party
Prof. Dominique de Quervain, MD (Director Division of Cognitive Neuroscience, University of Basel) — Sponsor-investigator
First posted
May 31, 2019
Start date
Jun 1, 2019
Primary completion
Jul 31, 2019
Completion
Sep 20, 2019
Last update
Oct 30, 2019

Study contacts

Dominique de Quervain, MD
study director · University of Basel, Division of Cognitive Neuroscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion